Gerdau S.A. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Gerdau S.A. Common Stock trades at $4.94 (market cap $9.38B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.1× Gerdau S.A. Common Stock's market cap, and Gerdau S.A. Common Stock pays the higher dividend (3.59%). Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GGB | REGN | |
|---|---|---|
Market Cap | $9.38B | $76.40B |
Volume | 13,301,134 | 626,381 |
Sector | Basic Materials | Health |
52-Week High | $5.17 | $852.03 |
52-Week Low | $3.15 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $11.33B | $71.12B |
Dividend Yield | 3.59% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →